AWM
ORMP icon

Apollon Wealth Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Apollon Wealth Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-20,000
Closed -$43.6K – 983
2023
Q1 		$43.6K Buy
+20,000
New +$63.5K ﹤0.01% 844

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Apollon Wealth Management's ORMP Position: Q2 2023 in Review

Apollon Wealth Management sold out of Oramed Pharmaceuticals (ORMP) in Q2 2023, closing a stake of 20,000 shares — an estimated $43.6K sold.

Apollon Wealth Management first reported a position in ORMP in Q1 2023 and held it in 1 quarter. The position peaked at $43.6K in Q1 2023. 50 funds tracked by Wall St. Rank hold ORMP as of Q2 2023.

  • Apollon Wealth Management reported no remaining Oramed Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Apollon Wealth Management sold 20,000 Oramed Pharmaceuticals shares in Q2 2023, an estimated $43.6K.
  • Apollon Wealth Management first reported a position in Oramed Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Apollon Wealth Management's Oramed Pharmaceuticals position peaked at $43.6K in Q1 2023.
  • 50 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2023.

Based on Apollon Wealth Management's 13F filing for Q2 2023, filed 4 Aug 2023.